Sandoz And Samsung Celebrate Stelara Rival’s EU Approval

Pyzchiva Biosimilar Version Of Ustekinumab Receives European Commission Nod

 
• By Dave Wallace

Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.

Red wooden figure waiting second in line with other wooden figures
Sandoz and Samsung's Pyzchiva is the second of many ustekinumab biosimilar filings to receive approval in the EU • Source: Shutterstock

More from Biosimilars

More from Products